Lampertheim, Germany

Roswitha Stenzel

This inventor holds 1 USPTO granted patent. Top assignee: Knoll Aktiengesellschaft. Active years: 2001.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 139(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Roswitha Stenzel

Introduction

Roswitha Stenzel is a notable inventor based in Lampertheim, Germany. She has made significant contributions to the field of medicine, particularly in the development of treatments for disorders characterized by elevated serum levels of interleukin-6. Her work has the potential to impact many lives through innovative therapeutic solutions.

Latest Patents

Stenzel holds a patent for the "Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6." This invention focuses on the application of TNF antagonists in producing drugs aimed at treating specific medical conditions. The patent highlights her commitment to advancing medical science and improving patient care.

Career Highlights

Roswitha Stenzel is associated with Knoll Aktiengesellschaft, a company known for its contributions to the pharmaceutical industry. Her role there has allowed her to collaborate with other talented professionals and further her research in innovative treatments.

Collaborations

Throughout her career, Stenzel has worked alongside esteemed colleagues such as Martin Kaul and Christa Raab. These collaborations have fostered a productive environment for innovation and have contributed to the success of her projects.

Conclusion

Roswitha Stenzel's work exemplifies the spirit of innovation in the medical field. Her patent and collaborations reflect her dedication to improving healthcare through scientific advancements. Her contributions are a testament to the impact that dedicated inventors can have on society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…